Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03589066 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic Study of LY03003 in Patients With Parkinson's Disease
A Phase 1 study, sponsored by Luye Pharma Group.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT03589066 is a Phase 1 study that has completed, run by Luye Pharma Group. The registered enrollment target is 24 participants.
The verdict
NCT03589066, a Phase 1 study, has completed, sponsored by Luye Pharma Group.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This is a Phase 1, open-label, parallel-group study to evaluate rotigotine pharmacokinetics, safety and tolerability following a single intramuscular dose of one of two different formulations of LY03003 in patients with Parkinson's disease.
Interventions
- DRUG LY03003
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2018-05-15 |
| Est. Completion | 2018-10-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03589066
The ClinicalTrials.gov registry entry for NCT03589066 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Luye Pharma Group, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LY03003 is the first listed.
NCT03589066 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03589066 about?
NCT03589066 is a clinical study titled "Pharmacokinetic Study of LY03003 in Patients With Parkinson's Disease". This is a Phase 1, open-label, parallel-group study to evaluate rotigotine pharmacokinetics, safety and tolerability following a single intramuscular dose of one of two different formulations of LY03003 in patients with Parkinson's disease.
What is the current status of trial NCT03589066?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2018-05-15. Estimated completion is 2018-10-31.
What interventions are being tested in trial NCT03589066?
The interventions under investigation include: LY03003 (DRUG).
Who is sponsoring clinical trial NCT03589066?
This trial is sponsored by Luye Pharma Group, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.